The SELEQT-HF (SELEnium and CoQ10 NuTrition for Heart Failure) Study Will Evaluate the Effect of Adding Selenium/and coQ10 on Top of Standard HF Therapy in Patients With HF and Will do so Using a Pragmatic, Registry Based Randomized Controlled Trial in the Netherlands.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1100 participants.
Also called NCT07234422
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,100 participants
- Sponsor
- Registry
-
NCT07234422
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Netherlands
- Registry status
- Recruiting
Technical summary
Registry record NCT07234422. Randomized; triple masking; primary purpose treatment. Start 2026-05-04 (actual); primary completion 2030-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The SELEQT-HF (SELEnium and CoQ10 NuTrition for Heart Failure) Study Will Evaluate the Effect of Adding Selenium/and coQ10 on Top of Standard HF Therapy in Patients With HF and Will do so Using a Pragmatic, Registry Based Randomized Controlled Trial in the Netherlands.
- Acronym
- SELEQT-HF
- Condition
- Heart Failure
- Intervention (Dietary supplement)
- Selenium/CoQ10
- Intervention (Drug)
- Matching Placebo (B)
- Lead sponsor
- Netherlands Heart Institute
- Collaborator
- University Medical Center Groningen
- Collaborator
- ZonMw: The Netherlands Organisation for Health Research and Development
- Collaborator
- Hartstichting
- Collaborator
- Pharma Nord
- Collaborator
- WCN (Werkgroep Cardiologische centra Nederland)
Record details
- Record id
cardio:ct-nct07234422- Content hash
7325c8168024ca2f70214871339995ec41c40aba67ef22f2ee8cde7365b3582c